This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Aripiprazole Worsens Psychosis: A Case Report

Sandeep Grover, MD; Pratap Sharan, MD; Nitin Gupta, MD

Published: December 15, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Aripiprazole is a second-generation antipsychotic medicationwith a unique mechanism of action. It acts as a functionalantagonist or functional agonist at dopamine and serotonin receptors,depending upon the level of the relevant neurotransmitterin the immediate environment, and for this reason, it isknown as a dopamine-serotonin system stabilizer.1 Due to thepartial-agonist D2 receptor activity of aripiprazole, it has beensuggested to worsen psychosis.2We report a case in which the unique mechanism of actionof aripiprazole probably contributed to relapse of psychoticsymptoms.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 8

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders


Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...